title: Inhibition of cPLA2 translocation and leukotriene C4 secretion by fluticasone propionate in exogenously activated human eosinophils.
abstract: We examined the effect of the highly lipophilic corticosteroid, fluticasone propionate (FP), in causing (1) inhibition of nuclear translocation of cytosolic phospholipase A2 (cPLA2), and (2) blockade of leukotriene C4 (LTC4) synthesis in isolated human eosinophils in vitro. Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml human recombinant interleukin-5 (rhIL-5) and activated with formyl-met-leu-phe (FMLP) + cytochalasin B (CB). At 24 h, stimulated LTC4 secretion from eosinophils was unchanged; however, when corrected for cell viability, LTC4 secretion decreased from 1,429 +/- 327 pg/10(6) cells to 762 +/- 113 pg/10(6) cells for eosinophils treated for 48 h with >/= 10(-)8 M FP (p < 0.003). FMLP/CB-stimulated translocation of cPLA2 to the nuclear envelope assessed by specific immunohistochemical staining also was blocked by FP. By contrast, membrane expression of annexin-1, which was not minimal at 30 min, was substantial at 48 h for eosinophils treated with > 10(-)10 M FP, and inhibition of LTC4 synthesis was reversed by exogenous arachidonic acid (AA). We find that FP causes a decrease in stimulated eosinophil secretion of LTC4 that is regulated by phospholipase A2 (PLA2). Inhibition of LTC4 synthesis precedes the global cytotoxic effects of FP as indicated by the simultaneous upregulation of annexin-1 expression. Inhibited stimulated secretion corresponds to inhibited translocation of cPLA2 to the nuclear envelope during cellular activation.
authors.affiliation: Section of Pulmonary and Critical Care Medicine, Department of Medicine, The University of Chicago, IL, USA.
authors.forename: A
authors.initials: A
authors.lastname: Sano
authors.forename: N M
authors.initials: NM
authors.lastname: Muñoz
authors.forename: H
authors.initials: H
authors.lastname: Sano
authors.forename: J
authors.initials: J
authors.lastname: Choi
authors.forename: X
authors.initials: X
authors.lastname: Zhu
authors.forename: B
authors.initials: B
authors.lastname: Jacobs
authors.forename: A R
authors.initials: AR
authors.lastname: Leff
mesh_terms: D000287:Administration, Topical; D000730:Androstadienes / Q000494:pharmacology*; D017302:Annexins / Q000378:metabolism; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D016718:Arachidonic Acid / Q000494:pharmacology; D001692:Biological Transport / Q000502:physiology; D002470:Cell Survival / Q000187:drug effects; D003600:Cytosol / Q000201:enzymology*; D004804:Eosinophils / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism / Q000502:physiology*; D000068298:Fluticasone; D005938:Glucocorticoids; D006801:Humans; D007425:Intracellular Membranes / Q000378:metabolism; D017997:Leukotriene C4 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D010741:Phospholipases A / Q000378:metabolism*; D054467:Phospholipases A2
chemical_list: D000730:Androstadienes; D017302:Annexins; D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D016718:Arachidonic Acid; D017997:Leukotriene C4; D000068298:Fluticasone; D010741:Phospholipases A; D054467:Phospholipases A2